Current News

Contact | Print version | Send article | RSS feed

Intercell and Merck expand alliance to develop prophylactic vaccine and antibody treatments against Group A Streptococcus

30 Oct 2006 - Intercell AG announced that it has extended its strategic partnership with Merck Sharp & Dohme Research Ltd., an affiliate of Merck & Co., Inc., to include development of a prophylactic vaccine against Group A Streptococcus infections.
 
The agreement is based on antigens that were discovered and validated by Intercell's proprietary bacterial Antigen Identification Program (AIP®). The agreement also includes an option for Merck to develop human monoclonal antibodies directed against antigens identified by Intercell to treat and protect against severe infections caused by Group A Streptococcus.
 
Under the terms of the agreement, Intercell will provide to Merck certain Group A Streptococcusspecific antigens identified by its Antigen Identification Program (AIP®) that have promising profiles in preclinical vaccine models. Intercell will receive an upfront payment of USD 9.5 million and is eligible to receive milestone payments up to USD 76 million over the term of the agreement. Intercell will also receive royalties on future net sales of the product.